National Cancer Institute

Recent papers from National Cancer Institute

1. Exploring Molecular Determinants of Long-Term Survival in Metastatic Gastric Cancer: An mRNA Expression Pilot StudyCurrent Issues in Molecular Biology · 2026
2. Early dynamics of eosinophils and the neutrophil-to-lymphocyte ratio are associated with severe immune-related adverse events during nivolumab therapy for metastatic renal cell carcinomaFrontiers in Immunology · 2026
3. Image-based Detection of Mismatch Repair Deficiency in Prostate Cancer Using Transfer LearningClinical Cancer Research · 2026
4. Identification of a novel, expressed, alternatively spliced FCER1G protein that inhibits receptor functionFrontiers in Immunology · 2026
5. Distributed apoptotic checkpoints in B cell selection, tolerance, and autoimmunityFrontiers in Immunology · 2026
6. Not all artificial intelligence large language models are created equal: heterogeneous performance in therapeutic decision-making for recurrent epithelial ovarian cancerInternational Journal of Gynecological Cancer · 2026
7. Survival Predictors in Cancer Patients With Bone Metastasis: Retrospective Cohort Single-Center StudyExperimental Oncology · 2026
8. Friend or foe: divergent immunomodulatory effects of metabolites derived from the virucidal zinc finger inhibitor SAMT-247Frontiers in Immunology · 2026
9. Longitudinal multi-omic dynamics in hospitalized COVID-19 patients based on disease severityGut Microbes Reports · 2026
10. Phase II study of olaparib plus durvalumab in EGFR-mutant NSCLC transformed to small cell lung cancerThe Oncologist · 2026
11. Interpreting Circulating Bile Acid Profiles in Pancreatic Cancer: The Role of Cholestasis and Its ManagementCancers · 2026
12. Associations of Age With Tumor Genomic Characteristics in Relapsed/Refractory Cancers Interrogated With the NCI-MATCH Trial Targeted Gene Panel AssayJCO Precision Oncology · 2026
13. Impact of Russian invasion on radiation therapy capacity in Ukraine: a national survey studyBMJ Global Health · 2026
14. Time-varying hazard rates reveal patterns of progression in HR+/HER2– metastatic breast cancer: Towards risk-adapted monitoringTranslational Oncology · 2026
15. Prognostic impact of PTEN status in recurrent IDH-wildtype glioblastoma receiving second-line therapyNeuro-Oncology Advances · 2026
16. Molecular Imaging and Radioligand Therapies in Pheochromocytomas and ParagangliomasEndocrine Related Cancer · 2026
17. Systemic Management of Adrenal Malignancies: Adrenocortical carcinoma and pheochromocytoma/paragangliomaEndocrine Connections · 2026
18. Circulating tumor DNA in early breast cancer: Evidence, challenges, next stepsCancer · 2026
19. Real-world implementation of a pre-consultation patient educational tool for intermediate risk prostate cancerClinical and Translational Radiation Oncology · 2026
20. Anti-Human Epidermal Growth Factor Receptor 2 therapies in metastatic colorectal cancer: a systematic review and meta-analysisThe Oncologist · 2026